[CAS NO. 59729-32-7] Citalopram hydrobromide

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [59729-32-7]

Catalog

HY-B1287

Brand

MCE

CAS

59729-32-7

DESCRIPTION [59729-32-7]

Overview

MDL	MFCD02101306
Molecular Weight	405.30
Molecular Formula	C20H22BrFN2O
SMILES	N#CC1=CC2=C(C(C3=CC=C(F)C=C3)(CCCN(C)C)OC2)C=C1.[H]Br

For research use only. We do not sell to patients.

5 Publications Citing Use of MCE

Summary

Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) . Citalopram hydrobromide inhibits 5-HT uptake into synaptosomes with an IC ₅₀ of 1.8 nM. Citalopram hydrobromideinhibits the 5-HT uptake in rabbit blood platelets with an IC ₅₀ of 14 nM. Antidepressant effect ^[1] .

In Vitro

Citalopram（25-150 μM) shows a concentration-dependent cytotoxicity on the viability of rat B104, human SH-SY5Y, IMR32 and Kelly neuroblastoma cell lines and human primary Schwann cells (HSC) ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	Rat B104, human SH-SY5Y, IMR32 and Kelly neuroblastoma cells
Concentration:	50, 100, 125, 150 μM for B104 cells 25, 50, 100, 125 μM for SH-SY5Y cells 25, 50, 100, 125, 150 μM for Kelly cells 25, 50, 100, 125 μM for IMR32 cells 50, 100, 125, 150 μM for HSCs
Incubation Time:	24 h ours
Result:	Significantly decreased B104 cell viability, 61%, 33% and 11% at respectively 100, 125 and 150 μM in B104 cell line. Drastically decreased SH-SY5Y cell viability, 17%, 1% at respectively 100 and 125 μM in SH-SY5Y cell line. Significantly decreased Kelly cell viability, 64%, 9% and 0% at respectively 100, 125 and 150 μM in Kelly cell line. Drastically decreased IMR32 cell viability, 36%, 1% and 0% at respectively 50, 100 and 125 μM in IMR32 cell line.

In Vivo

Acute administration of Citalopram (1-10 mg/kg, i.p. 1 h before an elevated plus-maze test) to Spontaneously Hypertensive rats (SHRs), Lewis (LEW) rats, and Wistar-Kyoto (WKY) rats, i.e., rat strains differing for their emotionality, promotes anxiety, and/or hypoactivity, except in WKY rats. In the three strains, such a pretreatment increased central 5-HT levels and/or decreased 5-hydroxyindoleacetic acid levels ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male rats from the SHR, LEW, and WKY strains, aged 6–8 weeks ^[3]
Dosage:	1, 3.3, or 10 mg/kg
Administration:	Injected i.p.
Result:	Increased significantly 5-HT in SHRs and WKY rats, and decreased 5-HIAA in all strains, in either a dose-dependent (LEW and WKY rats) or a dose-independent (SHRs) manner.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00249886	Sunnybrook Health Sciences Centre	Major Depression	September 2002	Phase 3
NCT01149980	Dr. Reddy´s Laboratories Limited	Healthy	October 2003	Phase 1
NCT04145076	King´s College London	Autism Spectrum Disorder	December 15, 2014	Not Applicable
NCT02269540	Centre for Addiction and Mental Health	Major Depressive Disorder	October 2014	Early Phase 1
NCT03511118	Duke University\|The Emmes Company, LLC\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Lactating Women on Select DOI\|Breastfed Infants of Mothers on Select DOI	October 4, 2018
NCT04097288	University Hospital Bispebjerg and Frederiksberg	Stress Urinary Incontinence\|Fecal Incontinence	September 17, 2019	Phase 1
NCT01937182	University of Aarhus\|Danish Council for Independent Research\|The Danish Regions Medicine Foundation	Stroke, Ischemic	September 2013	Phase 2
NCT00477165	Stanford University	Irritable Bowel Syndrome	April 2001	Phase 2
NCT00208572	Walter Reed Army Medical Center\|The Defense and Veterans Brain Injury Center\|VA Palo Alto Health Care System\|Hunter Holmes McGuire VA Medical Center\|United States Naval Medical Center, San Diego\|59th Medical Wing\|James A. Haley Veterans Administration Hospital	Traumatic Brain Injury	November 2003	Not Applicable
NCT01153165	Liam Heaney\|Asthma UK\|Belfast Health and Social Care Trust	Asthma	November 2010	Not Applicable
NCT00249405	University of Cincinnati\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Alcoholism\|Alcohol Abuse	February 2005	Phase 2
NCT01951053	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Healthy	January 2010	Phase 1
NCT01575158	University of Aarhus\|Danish University Antidepressant Group	Depression	October 1997	Not Applicable
NCT01367756	Hoffmann-La Roche	Healthy Volunteer	May 2011	Phase 1
NCT00896441	Stanford University	Depression\|Mood Disorders\|Depressive Disorder	February 2009	Not Applicable
NCT00086645	Boston University\|National Institute of Mental Health (NIMH)	Autistic Disorder	April 2004	Phase 2
NCT01179568	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)\|American Foundation for Suicide Prevention	Complicated Grief\|Bereavement	March 2010	Phase 2
NCT01099592	Centre hospitalier de l´Université de Montréal (CHUM)\|Canadian Institutes of Health Research (CIHR)\|Centre de Recherche du Centre Hospitalier de l´Université de Montréal\|Montreal Heart Institute	Acute Coronary Syndrome\|Major Depressive Episode	November 2010	Phase 4
NCT03779789	Azienda Ospedaliera Universitaria Integrata Verona\|University of Catania	Major Depressive Disorder	February 1, 2019	Phase 4
NCT02320240	Canadian Network for Observational Drug Effect Studies, CNODES\|Drug Safety and Effectiveness Network, Canada\|Canadian Institutes of Health Research (CIHR)	Depression\|Acute Kidney Injury	June 2013
NCT05346445	Hospital Regional 1o de Octubre\|Universidad Nacional Autonoma de Mexico\|National Polytechnic Institute, Mexico	Postmenopause\|Hot Flashes	January 20, 2021	Not Applicable
NCT00977353	China Medical University Hospital\|National Science Council, Taiwan	Major Depressive Disorder\|Depression\|Major Depression	April 2009	Phase 2
NCT00865943	Actavis Inc.	Healthy	July 2003	Phase 1
NCT01300364	Fundació Sant Joan de Déu\|Centro de Investigación Biomédica en Red de Salud Mental	Schizophrenia	November 2008	Phase 4
NCT00939835	Torrent Pharmaceuticals Limited	Healthy		Phase 1
NCT00018902	University of Pittsburgh\|National Institute of Mental Health (NIMH)	Depression	January 2001	Phase 2\|Phase 3
NCT01557946	Mclean Hospital	MDD\|Citalopram\|Major Depressive Disorder	March 2012	Phase 4
NCT03499171	Universitaire Ziekenhuizen KU Leuven	GERD	May 27, 2019	Phase 4
NCT02330068	Mayo Clinic	Major Depressive Disorder, Bipolar I and Bipolar II	December 2014
NCT04497168	University of Michigan\|National Institute on Aging (NIA)	Parkinson Disease	April 1, 2021	Phase 2
NCT00217828	University of Pittsburgh\|National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Heart Diseases	March 2002	Not Applicable
NCT01946607	University of Oxford\|Medical Research Council Cognition and Brain Sciences Unit	Antidepressive Agents, Second-Generation	July 2009	Not Applicable
NCT04846829	University of California, Los Angeles	Major Depressive Disorder	April 24, 2017	Early Phase 1
NCT03607331	China Academy of Chinese Medical Sciences	Depression\|Depressive Symptom\|Depressive Disorder	September 17, 2018	Early Phase 1
NCT00317746	Marina Klein\|Ontario HIV Treatment Network\|Schering-Plough\|CIHR Canadian HIV Trials Network\|McGill University Health Centre+Research Institute of the McGill University Health Centre	Depression\|HIV Infections\|Hepatitis C	November 2006	Phase 3
NCT03516604	University of Oxford\|Medical Research Council\|Pfizer	Depression, Unipolar	May 16, 2018	Phase 1
NCT01658228	New York State Psychiatric Institute\|National Institute on Aging (NIA)	Depression\|Mild Cognitive Impairment	September 2011	Phase 4
NCT00898807	JHSPH Center for Clinical Trials\|National Institute on Aging (NIA)\|National Institute of Mental Health (NIMH)	Alzheimer´s Disease\|Agitation	July 2009	Phase 3
NCT02237937	HolsboerMaschmeyer NeuroChemie GmbH\|Max-Planck-Institute of Psychiatry	Major Depression	September 2011	Phase 4
NCT02655354	University of Washington\|National Institutes of Health (NIH)\|National Institute of Mental Health (NIMH)\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Posttraumatic Stress Disorder\|Depression\|Alcohol-Related Disorders\|Suicidal Ideation\|Substance-Related Disorders\|Mild Cognitive Impairment\|Quality of Life\|Pain\|Wounds and Injury\|Brain Injuries\|Chronic Disease	October 2015	Not Applicable
NCT00067301	National Center for Complementary and Integrative Health (NCCIH)	Major Depression	September 2003	Phase 3
NCT00009204	Bruce Pollock\|National Institute of Mental Health (NIMH)\|University of Pittsburgh	Dementia\|Alzheimer Disease\|Dementia, Vascular	September 1995	Phase 3
NCT03278938	New York State Psychiatric Institute	Depressive Illness	June 29, 2012	Phase 4
NCT01254305	Forest Laboratories	Major Depressive Disorder	April 2011	Phase 2
NCT01041274	NYU Langone Health\|National Institute of Mental Health (NIMH)	Schizophrenia\|Schizophreniform Disorder	January 2010	Phase 4
NCT02386475	Hospital de Granollers	Stroke	January 2015	Phase 4
NCT01764867	Shanghai Mental Health Center	Major Depressive Disorder	June 2012	Phase 4
NCT02022709	Shanghai Mental Health Center\|Shanghai Municipal Science and Technology Commission\|Shanghai Jiao Tong University School of Medicine	Obsessive-Compulsive Disorder\|Anxiety Disorders\|Mental Disorders	January 2014	Phase 4
NCT00838305	California Pacific Medical Center Research Institute	MDMA Mechanism of Action	February 2009	Not Applicable
NCT01978782	Radboud University Medical Center	HIV\|Depression	January 2014	Phase 1
NCT02473250	New York State Psychiatric Institute	Bipolar Disorder	January 2015	Phase 4
NCT01601912	Vrije Universiteit Brussel	Whiplash Injuries	February 2013
NCT01568684	National Institute of Mental Health (NIMH)\|National Institutes of Health Clinical Center (CC)	Depressive Disorder\|Depressive Disorder, Major\|Depression	March 12, 2012	Phase 1
NCT00226694	University of Cincinnati\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Alcoholism\|Stress\|Alcohol Dependence	September 2003	Not Applicable
NCT00073658	University of Pittsburgh\|National Institute of Mental Health (NIMH)	Dementia	January 2000	Phase 2
NCT00865085	Actavis Inc.	Healthy	June 2003	Phase 1
NCT00047450	Veterans Medical Research Foundation\|National Institute of Mental Health (NIMH)	Schizophrenia	September 2001	Not Applicable
NCT00666757	Eli Lilly and Company\|Boehringer Ingelheim	Depression	May 2008	Phase 4
NCT02179268	Guiyang Medical University	Bone Mineral Density Quantitative Trait Locus 7	March 2012	Phase 3
NCT03282110	China Academy of Chinese Medical Sciences	Depression; Psychoneurotic\|Pain	November 30, 2017	Early Phase 1
NCT00271596	University of Iowa\|National Institute of Neurological Disorders and Stroke (NINDS)\|Cure Huntington´s Disease Initiative (CHDI)\|University of Rochester\|Mayo Clinic	Huntington Disease\|Chorea\|Executive Dysfunction	November 2005	Phase 2
NCT01216449	Rotman Research Institute at Baycrest\|Centre for Addiction and Mental Health\|University of Toronto	Healthy Young and Elderly Volunteers	April 2009	Not Applicable
NCT03538691	Otsuka Pharmaceutical Development & Commercialization, Inc.	Major Depressive Disorder	July 13, 2018	Phase 3
NCT05271084	Hawler Medical University	Major Depressive Disorder	November 10, 2021	Phase 1\|Phase 2
NCT04776226	Ege University	Stroke Recurrence\|Cardiovascular Events\|Depression	February 11, 2017	Not Applicable
NCT00218036	The University of Texas Health Science Center, Houston\|National Institute on Drug Abuse (NIDA)\|University of Texas	Cocaine Abuse\|Opiate Dependence	July 2006	Phase 2
NCT00297505	National Institute on Drug Abuse (NIDA)	Cocaine Dependence	April 2001	Phase 2
NCT00834834	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)	Borderline Personality Disorder\|Suicide	March 2009	Phase 4
NCT01473381	Forest Laboratories	Major Depressive Disorder	December 2011	Phase 4
NCT00893256	National Institute of Mental Health and Neuro Sciences, India	Schizophrenia\|Negative Symptoms	December 2004	Phase 4
NCT00254020	Sunnybrook Health Sciences Centre	Depression	June 2005	Phase 4
NCT00021528	National Institute of Mental Health (NIMH)	Depression	July 2001	Phase 4
NCT00955474	Massachusetts General Hospital	Major Depressive Disorder With Psychotic Features	September 2008	Phase 4
NCT01154647	Vrije Universiteit Brussel\|Research Foundation Flanders\|Universiteit Antwerpen\|University Hospital, Antwerp\|Artesis University College, Antwerp	Fatigue Syndrome, Chronic\|Fibromyalgia\|Arthritis, Rheumatoid	September 2010	Not Applicable
NCT01189812	Columbia Northwest Pharmaceuticals	Major Depressive Disorder\|Dysthymia\|Depression Not Otherwise Specified\|Borderline Personality Disorder	March 2010	Phase 2
NCT00993876	Zentrum für Integrative Psychiatrie\|German Research Foundation	Cognitive Performance in Major Depression	August 2005	Not Applicable
NCT05041582	Chih-Wei Tang\|Taipei Veterans General Hospital, Taiwan\|University of Oxford\|Far Eastern Memorial Hospital	Stroke\|Motor	September 1, 2021	Phase 3
NCT00254007	Sunnybrook Health Sciences Centre\|Ontario Mental Health Foundation	Depression\|Traumatic Brain Injury	July 2003	Phase 4
NCT00692445	Targacept Inc.	Major Depressive Disorder\|Depression	June 2008	Phase 2
NCT00562861	Tufts Medical Center\|National Institute of Mental Health (NIMH)	Bipolar Disorder\|Bipolar Depression	November 2007	Phase 2\|Phase 3
NCT01725048	UNC Lineberger Comprehensive Cancer Center	Major Depressive Disorder\|Neoplasms	January 2011	Early Phase 1
NCT03899285	Ciusss de L´Est de l´�le de Montréal	Major Depressive Disorder	January 8, 2018	Phase 2
NCT01149967	Dr. Reddy´s Laboratories Limited	Healthy	October 2003	Phase 1
NCT02092974	Charite University, Berlin, Germany	Healthy Young and Older Adults	April 2014	Phase 1
NCT00108563	US Department of Veterans Affairs\|VA Office of Research and Development	Hepatitis C\|Depression	October 2003	Phase 4
NCT01896349	Hospital de Clinicas de Porto Alegre	Treatment Resistant Depression	April 2013	Not Applicable
NCT00162916	Ontario Neurotrauma Foundation	Depression	May 2005	Phase 4
NCT00048815	Massachusetts General Hospital\|National Institute of Mental Health (NIMH)\|National Center for Complementary and Integrative Health (NCCIH)\|Office of Dietary Supplements (ODS)	Depression	February 2003	Not Applicable
NCT02374567	Hannover Medical School	Dementia\|Depression\|Schizophrenia\|Psychosomatic Disorders\|Anxiety Disorders	January 2015	Phase 3
NCT00376051	Sunnybrook Health Sciences Centre\|Alzheimer Society of Canada	Frontotemporal Dementia	September 2006	Phase 4
NCT02000726	University of Michigan	Depression	July 2013	Phase 2
NCT02113943	Institut National de la Santé Et de la Recherche Médicale, France	Normal Volunteers	April 2014	Phase 2
NCT00351910	AstraZeneca	Major Depressive Disorder	May 2006	Phase 3
NCT01919216	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)	Major Depressive Disorder	January 2010	Phase 4
NCT01424384	GlaxoSmithKline	Depressive Disorder and Anxiety Disorders	September 19, 2008	Phase 1
NCT00825825	Michael Henry, MD\|Forest Laboratories\|Steward St. Elizabeth´s Medical Center of Boston, Inc.	Antidepressant Activity in Healthy Volunteers	May 2007	Phase 4
NCT01778686	Gitte Moos Knudsen\|Rigshospitalet, Denmark	Healthy	January 2013	Not Applicable
NCT00015548	National Institute of Mental Health (NIMH)	Alzheimer´s Disease	March 2001	Not Applicable
NCT00269334	National Health Research Institutes, Taiwan\|National Science Council, Taiwan\|Taipei Medical University WanFang Hospital\|Chang Gung Memorial Hospital\|Jing-Ho Mental Hospital, Taiwan\|Tsyr-Huey Mental Hospital	Major Depression	December 2005	Phase 4
NCT00188396	University Health Network, Toronto\|Ontario Mental Health Foundation	Major Depressive Disorder\|Depression	April 2004	Not Applicable
NCT03907215	Idorsia Pharmaceuticals Ltd.	Healthy	April 9, 2019	Phase 1
NCT01436643	Novartis Pharmaceuticals\|Novartis	Depression\|Relapsing-remitting Multiple Sclerosis	November 2011	Phase 4
NCT04161209	University of Oxford\|University of Bath	Depression\|Depressive Disorder\|Mental Disorder\|Antidepressive Agents\|Cognition\|Stress	October 11, 2019	Not Applicable
NCT04766229	University College Dublin\|Irish Cancer Society\|Big Health Inc.	Menopause\|Cancer\|Insomnia	June 21, 2021	Phase 2
NCT03746691	Universitaire Ziekenhuizen KU Leuven	Gastro Esophageal Reflux	February 1, 2017	Phase 4
NCT00613470	Mayo Clinic\|National Institute of General Medical Sciences (NIGMS)\|National Center for Research Resources (NCRR)	Depression	March 2005	Phase 1
NCT04355455	Universitaire Ziekenhuizen KU Leuven	Gastroesophageal Reflux	July 2011	Not Applicable
NCT01535573	Joy Schmitz\|National Institute on Drug Abuse (NIDA)\|The University of Texas Health Science Center, Houston	Cocaine Dependence	December 2010	Phase 2
NCT00532519	Hadassah Medical Organization	Prurigo Nodularis		Not Applicable
NCT02080832	Virginia Commonwealth University\|The University of Texas Health Science Center, Houston\|National Institute on Drug Abuse (NIDA)	Cocaine Dependence	February 2010	Phase 2
NCT00794040	National Institute of Mental Health (NIMH)\|National Institutes of Health Clinical Center (CC)	Mood Disorder\|Mental Disorder Diagnosed in Childhood\|Attention Deficit and Disruptive Behavior Disorder\|Attention Deficit Hyperactivity Disorder	November 17, 2008	Phase 2
NCT03854578	Boehringer Ingelheim	Depressive Disorder, Major	March 12, 2019	Phase 1
NCT00538889	Wyeth is now a wholly owned subsidiary of Pfizer	Healthy	August 2007	Phase 1
NCT04590612	Western University, Canada	Parkinson Disease\|Depression	January 2021	Not Applicable
NCT00962039	John V. Campo, M.D.\|National Institute of Mental Health (NIMH)\|Nationwide Children´s Hospital	Abdominal Pain\|Anxiety	July 2004	Phase 2\|Phase 3
NCT00221494	Mark Frye\|University of California, Los Angeles\|Mayo Clinic	Depression	January 2004	Phase 4
NCT00363909	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Breast Cancer\|Hot Flashes\|Psychosocial Effects of Cancer and Its Treatment	November 2006	Phase 3
NCT02028026	Massachusetts General Hospital	Major Depressive Disorder\|Anxiety\|Comorbidity	April 2013	Phase 4
NCT00864890	Actavis Inc.	Healthy	June 2003	Phase 1
NCT00774813	Kalaco Scientific, Inc.	Depression	October 2007	Phase 2
NCT00930293	University of Pittsburgh\|National Institute of Mental Health (NIMH)	Depression\|Anxiety	July 2009	Not Applicable
NCT01657760	VA Office of Research and Development	Alcohol Dependence	May 1, 2014	Phase 1
NCT01742832	University of Chicago	Major Depressive Disorder	May 2013	Phase 2
NCT02893371	University of New Mexico\|Patient-Centered Outcomes Research Institute\|Montana State University\|National Alliance on Mental Illness Montana\|CGStat LLC\|Risk Benefit Statistics LLC\|National Alliance on Mental Illness New Mexico\|National Alliance on Mental Illness Westside Los Angeles	Bipolar Disorder	September 2016
NCT00433121	Sykehuset Innlandet HF\|Demensforbundet, Norway	Dementia	September 2006	Phase 4
NCT00150527	Queen´s University\|H. Lundbeck A+S	Healthy	September 2005
NCT00609531	University of North Carolina, Chapel Hill\|National Institute of Mental Health (NIMH)	Autism Spectrum Disorders	January 2007	Phase 1
NCT02825342	Evangelismos Hospital	Chest Pain Rule Out Myocardial Infarction	March 2014	Phase 4
NCT00080158	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)	Depression\|Suicide, Attempted	March 2004	Phase 2\|Phase 3
NCT02711215	Medical University of Vienna	Major Depressive Disorder	May 2015	Phase 4
NCT05063604	Hospital Universitari de Bellvitge\|Institut Català d´Oncologia	Breast Cancer\|Major Depressive Episode	May 10, 2022	Phase 2
NCT01312922	PharmaNeuroBoost N.V.	Major Depressive Disorder	September 2011	Phase 3
NCT00047671	National Institute of Mental Health (NIMH)	Depression	June 2002	Phase 4
NCT00667121	Mayo Clinic\|National Cancer Institute (NCI)	Breast Cancer\|Depression\|Hot Flashes\|Psychosocial Effects of Cancer and Its Treatment	March 16, 2011
NCT04975724	Fidia Farmaceutici s.p.a.	Major Depressive Disorder	April 18, 2019	Phase 4
NCT04777838	University of Coimbra\|Instituto de Investigación Biomédica de Salamanca	Muscle Type Temporomandibular Disorders\|Myofascial Pain of the Masticatory Muscles	March 2021	Phase 2\|Phase 3
NCT00672659	PharmaNeuroBoost N.V.	Depression	February 2008	Phase 2
NCT01667744	Henry Ford Health System	Acute Coronary Syndrome	January 2018	Phase 1\|Phase 2
NCT01716221	University of Colorado, Denver	Friedreich Ataxia	October 2012	Phase 4
NCT00602290	University of California, Los Angeles\|National Institute of Mental Health (NIMH)	Depression	February 2008	Phase 4
NCT04169230	University of Oxford\|University of Bath	Molecular Mechanisms of Pharmacological Action\|Depression\|Depressive Disorder\|Mental Disorder\|Antidepressive Agents\|Cognition	October 11, 2019	Not Applicable
NCT00044798	University of Iowa\|National Institute of Mental Health (NIMH)	Depressive Disorder\|Depression	September 2001	Phase 3
NCT00594269	Sykehuset Innlandet HF\|Ullevaal University Hospital\|Eikertun Nursing Home\|University of Bergen\|Innlandet Hospital Trust, Sanderud\|Innlandet Hospital Trust, Reinsvoll\|Diakonhjemmet Hospital\|Sykehuset Telemark\|The Nordmøre and Romsdal Hospital Trust\|Songdalstunet Nursing Home\|Sykehuset Buskerud HF\|Kroken Nursing Home, Tromsø\|Kløveråsen, Bodø\|Bjørgene Omsorgssenter, Haugesund\|Alesund Hospital	Dementia	August 2008	Phase 4
NCT00369746	New York State Psychiatric Institute\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Major Depressive Disorder\|Alcohol Use Disorder	September 2006
NCT01032083	Imperial College London\|University of Manchester\|University of Southampton\|King´s College London\|University of Oxford\|University College, London\|University of Bristol	Schizophrenia	July 2011	Phase 4
NCT00876226	University of Nebraska	Short Bowel Syndrome	May 2010	Not Applicable
NCT00940238	Torrent Pharmaceuticals Limited	Healthy		Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 38 mg/mL ( 93.76 mM )

H ₂ O : 10 mg/mL ( 24.67 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4673 mL	12.3365 mL	24.6731 mL
5 mM	0.4935 mL	2.4673 mL	4.9346 mL
10 mM	0.2467 mL	1.2337 mL	2.4673 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 110 mg/mL (271.40 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.17 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, hydrobromide (1:1)

5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, monohydrobromide

Citalopram hydrobromide

Seropram

Cipramil

Celexa

Cipram

Lupram

Apertia

Sepram

Lu 10-171B

Elopram

Prisdal

(±)-Citalopram hydrobromide

Lecital

S-Pram

Pramcit

Cheer

Citopram

[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-isobenzofuran-5-carbonitrile hydrobromide

1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile hydrobromide